Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives-Reference-Cited by-同舟云学术

Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives

Published:2021-07-01 Issue:1 Volume:1 Page:6-9
ISSN:2749-9642
Container-title:Medical Review
language:en
Short-container-title:

Author:

Zhou Jun¹²,Ren Zhuoying¹²,Xu Jie¹,Zhang Jifeng¹,Chen Y. Eugene¹²^ORCID

Affiliation:

1. Center for Advanced Models for Translational Sciences and Therapeutics , University of Michigan Medical Center , Ann Arbor 48109, MI , USA

2. Department of Pharmacology , University of Michigan Medical Center , Ann Arbor 48109, MI , USA

Abstract

Abstract Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C3 (APOC3), angiopoietin Like 3 (ANGPTL3) and inducible degrader of the low-density lipoprotein receptor (IDOL) have demonstrated the benefits and advantages of GETx in managing atherosclerosis. Here we present our views on this brand new therapeutic option for cardiovascular diseases (CVD).

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/mr-2021-0010/pdf

Reference19 articles.

1. Jacinto, FV, Link, W, Ferreira, BI. CRISPR/Cas9-mediated genome editing: from basic research to translational medicine. J Cell Mol Med 2020;24:3766–78. https://doi.org/10.1111/jcmm.14916.

2. Crispr Developers Win 2020 Nobel Prize for Chemistry. Am J Med Genet A 2021;185:8–9. https://doi.org/10.1002/ajmg.a.61645.

3. Gupta, RM. One-shot, one cure with genome editing for dyslipidemia. Circ Cardiovasc Genet 2014;7:967–8. https://doi.org/10.1161/circgenetics.114.000958.

4. Nishiga, M, Qi, LS, Wu, JC. Therapeutic genome editing in cardiovascular diseases. Adv Drug Deliv Rev 2021;168:147–157. https://doi.org/10.1016/j.addr.2020.02.003.

5. King, A. A CRISPR edit for heart disease. Nature 2018;555:S23–5. https://doi.org/10.1038/d41586-018-02482-4.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into Prime Editing Technology: A Deep Dive into Fundamentals, Potentials, and Challenges;Human Gene Therapy;2024-07-01

2. Navigating the prime editing strategy to treat cardiovascular genetic disorders in transforming heart health;Expert Review of Cardiovascular Therapy;2024-03-03

3. The Long and Winding Road to Cardiac Regeneration;Applied Sciences;2023-08-20

4. Recent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering;Cells;2022-07-13

5. Cell–cell crosstalk in the heart;Medical Review;2021-10-01